PUBLISHER: TechNavio | PRODUCT CODE: 2144556
PUBLISHER: TechNavio | PRODUCT CODE: 2144556
The global breast cancer liquid biopsy testing devices market is forecasted to grow by USD 1226867.5 thousand during 2025-2030, accelerating at a CAGR of 24.3% during the forecast period. The report on the global breast cancer liquid biopsy testing devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expansion of companion diagnostic indications, rising prevalence of breast malignancies, technological integration of ai and digital polymerase chain reaction.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 23.7% |
| CAGR | 24.3% |
| Incremental Value | $1226867.5 thousand |
Technavio's global breast cancer liquid biopsy testing devices market is segmented as below:
By Type
By End-User
By Material
Geography
This study identifies the companion diagnostics driving clinical adoption as one of the prime reasons driving the global breast cancer liquid biopsy testing devices market growth during the next few years. Also, technological advancements in multiomics and shift toward minimal residual disease will lead to sizable demand in the market.
The report on the global breast cancer liquid biopsy testing devices market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global breast cancer liquid biopsy testing devices market vendors that include Agilent Technologies Inc., Bio Rad Laboratories Inc., Bio Techne Corp., Burning Rock Biotech Ltd., Caris Life Sciences Inc., Cellbox Solutions GmbH, Exact Sciences Corp., F. Hoffmann La Roche Ltd., Genecast Biotechnology Co. Ltd., Guardant Health Inc., Illumina Inc., Laboratory Holdings Inc., Menarini Silicon Biosystems, Myriad Genetics Inc., Natera Inc., NeoGenomics Laboratories Inc., Predicine Inc., QIAGEN N.V., SeekIn Inc., Sysmex Corp., Thermo Fisher Scientific Inc., Veracyte Inc.. Also, the global breast cancer liquid biopsy testing devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.